COMBINED TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG CANCER AND MOLECULAR ASPECTS OF CHEMORESISTANCE
##article.numberofdownloads## 38
##article.numberofviews## 606
PDF (Русский)

Keywords

COMBINED TREATMENT
NON-SMALL CELL LUNG CANCER
NEOADJUVANT CHEMOTHERAPY
CHEMORESISTANCE
MONORESISTANCE GENES
ABC-TRANSPORTERS

How to Cite

Miller, S., Rodionov, Y., Tuzikov, S., Yefteev, L., Yumov, Y., Tsyganov, M., Litvyakov, N., Frolova, I., Cherdyntseva, N., Velichko, S., & Goldberg, A. (2019). COMBINED TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG CANCER AND MOLECULAR ASPECTS OF CHEMORESISTANCE. Voprosy Onkologii, 65(3), 393–398. https://doi.org/10.37469/0507-3758-2019-65-3-393-398

Abstract

We analyzed the results of treatment of 68 patients with NSCLC stage III, of which the main group included 36 patients with perioperative chemotherapy vinorelbin / carboplatin. The control group included 32 patients who underwent only surgical treatment. The correlation of monoresistance and multidrug resistance (MDR) genes expression with clinical and morphological parameters of tumor process and with the frequency of distant metastasis was studied. Results. The three - year relapse-free and overall survival in the study group was 60.0±13.8% and 80.0±8.5 %, in the control group-35.7±25.4% and 50.0±18.9%, respectively. The relationship between the expression genes of the studied MDR genes and monoresistance with the main clinical and morphological parameters of patients and the frequency of metastasis was established. Conclusion. The results of the study show a higher efficiency of combined treatment of NSCLC due to a significant reduction in the number of long-term metastases and local recurrences and, accordingly, improved overall and relapse-free survival. Monoresistance anMDR genes play an important role in NSCLC chemoresistance, so the study of the expression level of these genes is important for the planning of personalized treatment.
https://doi.org/10.37469/0507-3758-2019-65-3-393-398
##article.numberofdownloads## 38
##article.numberofviews## 606
PDF (Русский)

References

Попова Н.О., Шаталова В.А., Симолина Е.И. и др. Клинический случай длительного лечения и наблюдения пациента с метахронным раком легкого//Сибирский онкологический журнал. -2011. -T 4. -C. 75-77.

Трахтенберг А.Х., Колбанов К.И. Рак легкого//М.: ГЭ-ОТАР-Медиа, 2012. -C. 160.

Чойнзонов Е.Л., Жуйкова Л.Д., Ананина О.А. и др. Выживаемость больных раком легкого на территории Томской области (2004-2013 гг.)//Сибирский онкологический журнал. -2017. -Т. 6(4). -С. 5-10.

Юмов Е.Л., Цыганов М.М., Литвяков Н.В. и др. Экспрессия генов множественной лекарственной устойчивости и монорезистентности при немелкоклеточном раке легкого//Сибирский онкологический журнал. -2014. -Т. 61(1). -С. 16-22.

Amiri-Kordestani L., Basseville A., Kurdziel K. et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies//Drug Resistance Update. -2012. -Vol. 15(1-2). -P. 50-61.

Douillard J., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ): a randomised controlled trial//The Lancet Oncology. -2006. -Vol. 7(9). -P 719-727.

Huang Z-L., Cao X., Luo R-Z. et al. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study//Oncology Letters. -2016. -Vol. 11(1). -P 299-305.

Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M. et al. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response//Cancer Chemotherapy and Pharmacology. -2013. -Vol. 71. -P. 153-163.

Olaussen K.A., Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape//Annals of Oncology. -2016. -Vol. 27(11). -P 2004-2016.

Postmus PE., Kerr K.M., Oudkerk M. et al. Early and locally advanced non-small-cell lung cancer (NsCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of Oncology. -2017. -Vol. 28 (SUPPL_4). -P iv1-iv21.

Su C., Zhou S., Zhang L. et al. ERCC1, RRM1, and BRCA1 Mrna expression levels and clinical outcome of advanced non-small cell lung cancer//Journal of Clinical Oncology. -2010. -Vol. 28(15_suppl). -P e18045-e18045.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2019